Guangyao Baiyunshan

Guangzhou Baiyunshan Pharmaceutical Holdings (广药白云山) is a major Chinese pharmaceutical and consumer-health group headquartered in Guangzhou, Guangdong. It is the listed flagship of Guangzhou Pharmaceutical Holdings Limited (GPHL, 广药集团), a state-owned enterprise group under the Guangzhou municipal government. The group's business spans traditional Chinese medicine (TCM), chemical drugs, biological products, health supplements, and consumer healthcare products, with a portfolio that includes well-known Chinese brands such as Baiyunshan (白云山), Wanglaoji (王老吉), Baiyunshan Chuanbei Pipa Gao, and others. The company operates through multiple subsidiaries and production bases, and its products are sold across China through hospitals, pharmacies, and retail channels, as well as exported to international markets. Its consumer-health segment, particularly herbal drinks and supplements, gives it a strong presence in the fast-moving consumer goods space alongside its pharmaceutical operations. As a listed company, Guangzhou Baiyunshan Pharmaceutical Holdings trades on both the Shanghai Stock Exchange (A-share, 600332) and the Hong Kong Stock Exchange (H-share, 0874). It is one of the larger pharmaceutical groups in China by revenue and is often grouped with other major TCM-focused enterprises. The group has pursued acquisitions and brand consolidation, and it invests in research and development of both traditional formulations and modern medicines. This dossier focuses on the commercial brand and corporate entity 广药白云山 / Guangzhou Baiyunshan Pharmaceutical Holdings. It is a brand and company entry, not a reference to the Baiyun Mountain landmark in Guangzhou, which shares the name.

Guangzhou Baiyunshan Pharmaceutical Holdings traces its roots to the consolidation of several Guangzhou-based pharmaceutical enterprises under Guangzhou Pharmaceutical Holdings Limited (GPHL), a state-owned group established by the Guangzhou municipal government. Over time, GPHL integrated a number of well-known local medicine brands, including Baiyunshan, into a single corporate structure. The listed entity, Guangzhou Baiyunshan Pharmaceutical Holdings, became the group's flagship vehicle on the capital markets, with shares traded on the Shanghai Stock Exchange and the Hong Kong Stock Exchange. The group expanded through organic growth and acquisitions, building a broad portfolio that spans traditional Chinese medicine, chemical pharmaceuticals, and consumer health products. A significant part of the group's consumer profile comes from its herbal tea and health-drink business, notably the Wanglaoji brand, which is one of China's best-known herbal beverage trademarks. The group has also invested in modernizing production, research and development, and distribution to serve both domestic and export markets. As a state-owned enterprise, the group operates within China's pharmaceutical regulatory framework and participates in national healthcare and TCM development initiatives. Its dual-listing status gives it access to both domestic and international capital.

• Baiyunshan Chuanbei Pipa Gao

  A traditional Chinese herbal syrup for throat and cough relief.

• Wanglaoji herbal tea

  A well-known Chinese herbal beverage brand.

• Baiyunshan health supplements

  A range of herbal and wellness supplements.

• 2022

  Three affiliated pharmaceutical companies cited by NHSA for inflating API prices and siphoning funds

  In 2022, China's National Healthcare Security Administration (NHSA) reported that Tianxin, Jingxiutang, and the Baiyunshan Pharmaceutical General Factory, all under Guangzhou Baiyunshan, had inflated the prices of active pharmaceutical ingredients and artificially raised drug prices to siphon off funds, involving 87 drugs. The companies were ordered to rectify the practices and undergo price credit evaluations. The matter was confined to the companies and sales practices named in the notice.

  Source

Read more

1. 1Guangzhou Baiyunshan Pharmaceutical Holdings official websitebysz.com.cn
2. 2Three affiliated pharmaceutical companies cited by NHSA for inflating API prices and siphoning fundscaixin.com
3. 3Three affiliated pharmaceutical companies cited by NHSA for inflating API prices and siphoning fundshealth.people.com.cn
4. 4Three affiliated pharmaceutical companies cited by NHSA for inflating API prices and siphoning fundsthepaper.cn